Toxicology Letters 337 (2021) 91–97
Contents lists available at ScienceDirect
Toxicology Letters
journal homepage: www.elsevier.com/locate/toxlet
Anticoagulant Micrurus venoms: Targets and neutralization
Daniel Dashevskya,b , Melisa Bénard-Vallec, Edgar Neri-Castroc , Nicholas J. Youngmana ,
Christina N. Zdeneka , Alejandro Alagónc, José A. Portes-Juniord, Nathaniel Franke,
Bryan G. Frya,*
a
Toxin Evolution Lab, School of Biological Sciences, University of Queensland, St Lucia, QLD 4072 Australia
Australian National Insect Collection, Commonwealth Science and Industry Research Organization, Canberra, ACT 2601 Australia
Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnologa, Universidad Nacional Autónoma de México, Av. Universidad 2001,
Cuernavaca, Morelos, 62210, Mexico
d
Laboratório de Coleções Zoológicas, Instituto Butantan, São Paulo 05503-900, Brazil
e
MToxins Venom Lab, 717 Oregon Street Oshkosh, WI 54902 USA
b
c
H I G H L I G H T S
Multiple coral snake (Micrurus) species possess anticoagulant venom.
Micrurus laticollaris venom is especially anticoagulant in plasma.
There is no strong phylogenetic pattern in the effect on clotting time.
Coralmyn antivenom is not effective against the anticoagulant venoms.
Varespladib is extremely effective against the anticoagulant venoms.
A R T I C L E I N F O
A B S T R A C T
Article history:
Received 20 August 2020
Received in revised form 30 October 2020
Accepted 9 November 2020
Available online 14 November 2020
Snakebite is a neglected tropical disease with a massive global burden of injury and death. The best
current treatments, antivenoms, are plagued by a number of logistical issues that limit supply and access
in remote or poor regions. We explore the anticoagulant properties of venoms from the genus Micrurus
(coral snakes), which have been largely unstudied, as well as the effectiveness of antivenom and a smallmolecule phospholipase inhibitor—varespladib—at counteracting these effects. Our in vitro results
suggest that these venoms likely interfere with the formation or function of the prothrombinase
complex. We find that the anticoagulant potency varies widely across the genus and is especially
pronounced in M. laticollaris. This variation does not appear to correspond to previously described
patterns regarding the relative expression of the three-finger toxin and phospholipase A2 (PLA2) toxin
families within the venoms of this genus. The coral snake antivenom Coralmyn, is largely unable to
ameliorate these effects except for M. ibiboboca. Varespladib on the other hand completely abolished the
anticoagulant activity of every venom. This is consistent with the growing body of results showing that
varespladib may be an effective treatment for a wide range of toxicity caused by PLA2 toxins from many
different snake species. Varespladib is a particularly attractive candidate to help alleviate the burden of
snakebite because it is an approved drug that possesses several logistical advantages over antivenom
including temperature stability and oral availability.
© 2020 Elsevier B.V. All rights reserved.
Keywords:
Coral snake
Elapid coagulotoxicity
Snakebite treatment
Varespladib
Prothrombinase inhibition
1. Introduction
* Corresponding author.
E-mail address: bgfry@uq.edu.au (B.G. Fry).
http://dx.doi.org/10.1016/j.toxlet.2020.11.010
0378-4274/© 2020 Elsevier B.V. All rights reserved.
Snakebite has recently been reclassified as a neglected tropical
disease and estimates of the global burden suggest that up to 5.5
million people are bitten every year, resulting in over 100,000
fatalities and over 400,000 permanent disabilities (Jean Philippe
Chippaux, 1998; Kasturiratne et al., 2008; Harrison et al., 2009;
92
D. Dashevsky et al. / Toxicology Letters 337 (2021) 91–97
Habib et al., 2015; WHO Neglected Tropical Diseases, 2019). These
estimates likely fall far short of the true scope of the problem due
to reporting issues and the socioeconomic conditions of the
locations where snakebite is particularly prevalent (Harrison et al.,
2009; Habib et al., 2015; Fry, 2018; Longbottom et al., 2018; BravoVega et al., 2019). Many of the most significant snake taxa from a
medical perspective, such as Bothrops, Daboia, or Echis possess
venoms that interfere with the coagulation of blood (Mukherjee,
2014; Rogalski et al., 2017; Sousa et al., 2018). Within these
venoms, the Group II Phospholipase A2 (PLA2) toxin family has
been found to frequently exhibit coagulotoxic activity (Verheij
et al., 1980; Alvarado and Gutiérrez, 1988). PLA2s have been
recruited into venoms independently several times including in
hymenopterans, vipers, and elapids such as coral snakes (Kini,
2003; Sunagar et al., 2015a, b; Baumann et al., 2018).
The coagulation of blood is the result of a complex cascade of
enzymes which activate others in turn to eventually cleave
fibrinogen into fibrin strands which form the actual clot (Weisel,
2005). In the simplest terms, two separate pathways can both
activate the final few steps of the coagulation cascade which is
known as the common pathway (Smith et al., 2015). In this
common pathway, the activated forms of the Factor V (FVa) and
Factor X (FXa) enzymes form a complex known as prothrombinase which activates prothrombin into thrombin, the final
enzyme which acts upon fibrinogen (Victor Hoffbrand and
Steensma, 2019). Procoagulant toxins can act by stimulating
any part of the three pathways, but anticoagulant toxins are
usually adapted to interfere with the common pathway because if
the toxin inhibited part of only one of the upstream pathways, the
other would still be able to form a proper clot and contribute to
positive feedback loops (Bittenbinder et al., 2018, 2019; Zdenek
et al., 2020a).
Research into venoms from snakes of the family Elapidae
have largely focused on the potent neurotoxins employed by
many of the most deadly species (Mohapatra et al., 2011; Utkin
et al., 2015). Stereotypically, elapid venoms were not thought
to be coagulotoxic, but modern research has shown that some of
the most medically significant Australian taxa such as Oxyuranus
and Pseudonaja employ potent procoagulants (Earl et al., 2015;
Trabi et al., 2015; Zdenek, op den Brouw et al., 2019, Zdenek, Hay
et al., 2019). However, some other elapid venoms, including
the Australian genera Denisonia and Pseudechis as well as the
African spitting cobras, have been reported to be anticoagulant as
well due to the activity of Group I PLA2 toxins (Bittenbinder et al.,
2018; Zdenek et al., 2020a; Kerns et al., 1999; Youngman et al.,
2019).
Bites of the genus Micrurus—often referred to as coral snakes—
can be quite dangerous but are a small proportion of the reported
snake bites within their range (Greene, 2020). Mortality from these
bites is usually due to neurotoxicity which can compromise the
respiratory system and lead to asphyxiation (Bucaretchi et al.,
2016; Canãs et al., 2017; Anwar and Bernstein, 2018; Bisneto et al.,
2020). The primary neurotoxins are from the three-finger toxin
(3FTx) and PLA2 toxin families, the relative prevalence of which in
the venom varies according to species and geography (Sanz et al.,
2019). The Group I PLA2s from elapid venoms have been associated
with diverse effects including neurotoxicity and anti-platelet
activity (Sunagar et al., 2015a). Some ancillary research has focused
on other aspects of their venom, including observations that some
coral snake venoms have anticoagulant effects on blood (Cecchini
et al., 2005; Oliveira et al., 2017; Rey-Suárez et al., 2017).
Additionally, some bite reports from the genus indicate mild to
moderate disturbances to the victim’s hemostasis (Manock et al.,
2008; Strauch et al., 2018; Silva et al., 2019), though there is no
direct evidence that these symptoms were caused by venom
proteins rather than preexisting conditions in the patients or as a
result of their ongoing treatment in the hospital. Of those patients
showing these coagulopathies, all display delayed clotting times or
wholly unclottable blood.
Currently, the only specific treatment for coral snake
envenomations is antivenom which has been demonstrated to
protect against the neurotoxicity of these venoms (Greene, 2020;
Yang et al., 2017; Castillo-Beltrán et al., 2019). While antivenoms
have saved countless lives, crucial limitations in their application
contribute to the global burden of snakebite. Antivenoms require
refrigeration, must be delivered intravenously, and depending on
the product may carry significant risk of side effects. Because of
these issues antivenoms must be delivered in a hospital setting,
but most snakebites occur in rural areas. Due to the barriers to
access this challenge presents, it is estimated that 80% of
snakebite deaths might occur outside of a hospital (Sharma
et al., 2004). Recently, a small molecule phospholipase inhibitor
known as varespladib (LY315920) has been shown to also protect
against elapid neurotoxicity (Lewin et al., 2016; Gutiérrez et al.,
2020). The orally bioavailable prodrug methyl-varespladib has
even been demonstrated to specifically rescue juvenile pigs from
Micrurus fulvius envenomation and restore their clotting function
to normal (Lewin et al., 2018). Given that M. fulvius venom is
primarily composed of PLA2 toxins (Margres et al., 2013; Vergara
et al., 2014), it makes sense that varespladib would inhibit the
symptoms of this venom. Varespladib has also been shown to
counteract anticoagulant PLA2 toxins from a range of other
medically significant snake taxa including elapids such as Naja,
Pseudechis, and Oxyuranus as well as viper genera such as Bitis,
Bothrops, Calloselasma, Daboia, Deinagkistrodon, and Echis (Bittenbinder et al., 2018; Zdenek et al., 2020a; Youngman et al., 2020; Xie
et al., 2020).
To better understand the anomalous coagulopathies observed
in some bite cases and potential treatments, we examine the
anticoagulant properties and targets of a range of Micrurus venoms
as well as the effectiveness of antivenom and varespladib for
inhibiting this activity.
Table 1
Mean clotting times standard deviation (N = 3) in seconds for clotting assays carried out on screening species. MAX indicates that all three replicates exceeded the
maximum read time of the machine (999 s).
Negative control
M. browni
M. diastema
M. distans
M. fulvius
M. laticollaris
M. obscurus
M. pyrrhrocryptus
M. tener
Plasma
clotting
Fibrinogen
destruction
FXa
inhibition
Thrombin
inhibition
Prothrombinase
inhibition
484.9 46.9
MAX
MAX
749.6 149.7
MAX
MAX
MAX
651.5 56.3
MAX
3.3 0.2
5.4 1.9
4.9 1.0
5.4 0.3
4.8 1.0
4.3 0.6
4.3 1.0
4.5 0.0
4.1 1.0
15.4 1.9
25.3 1.1
21.1 0.7
22.9 1.9
22.8 1.5
26.7 0.9
25.3 1.1
19.0 0.8
23.0 1.5
57.9 0.8
52.1 5.2
54.5 5.3
58.1 11.3
52.4 0.9
58.4 9.0
53.5 4.5
56.7 8.2
56.5 4.9
16.8 0.2
28.8 0.6
35.6 2.9
22.2 0.9
59.8 3.0
147.4 16.4
65.3 4.0
31.0 0.6
51.3 7.3
D. Dashevsky et al. / Toxicology Letters 337 (2021) 91–97
93
2. Results
Initial anticoagulation screening assays showed that some
Micrurus venoms, when added to plasma, raised the spontaneous
clotting time from 484.0 46.9 s to more than 999 s (the maximum
machine read time of our assay, Table 1). Further screening
conducted by incubating the venoms with specific clotting factors
(FXa, thrombin, or fibrinogen) showed slight increases in clotting
time compared to controls, however for each of these factors the
most effective venom still clotted in less than twice the time of the
negative controls (Table 1). These slight effects were small in
comparison to our final assay where we incubated the venom with
plasma and directly stimulated clot formation by the addition of
FXa; in this assay the most potent venom (M. laticollaris) delayed
clotting times 9 compared to the negative controls and the
average across all the screening venoms was over 3 the control
value (Table 1). These effects were dose-dependent and varied
greatly between species (Fig. 1A). M. laticollaris venom produced
much longer clotting than other species, and an additional four
species M. fulvius, M ibiboboca, M. obscurus, and M. tener were less
potent than
M. laticollaris but still well above the negative control while M.
altirostris, M. browni, both samples of M. corallinus, M. diastema, M.
distans, M. pyrrhocryptus, and M. surinamensis had little to no effect.
For each of the five species that showed a sizable effect, the area
under the dose-response curve was significantly different (Tukey’s
HSD, p < 0.002 in every species) from that of the negative control.
These results did not follow a strong phylogenetic pattern (Fig. 1B).
Analysis of variance tests conducted within each species
concluded that incubating these five anticoagulant venoms
with Coralmyn antivenom (Fig. 2) did not have a significant
effect (Tukey’s HSD, p > 0.05) compared to the venom alone in
all species except M. ibiboboca (Tukey’s HSD, p < 0.0001). In
contrast to the overall inefficacy of the antivenom we tested,
varespladib significantly reduced the anticoagulant effect in each
species (Tukey’s HSD, p < 0.001). The values observed for the
varespladib treatment did not vary significantly between any of
the species or the negative control (p > 0.1) and the negative
control values did not vary significantly between the three
treatments (p > 0.05).
To test the importance of phospholipid to our results we again
used the same assay, but kept the concentration of M. laticollaris
mg
venom at 20 mL
and instead varied the amount of phospholipid
(Fig. 3). The exact quantity of phospholipid is not provided by the
manufacturer so we report the relative concentration compared to
the standard assay. The plasma we use contains some small
amounts of phospholipid (Krawczyk et al., 1996), so even when we
add no additional phospholipid, the negative controls are still able
to form clots. There is a clear negative relation between the
concentration of phospholipid and the clotting time in the
presence of M. laticollaris venom.
Finally, in vivo experiments showed no evident alteration in
coagulation when mice were injected intravenoulsy or intraperitoneally with M. laticollaris venom (See Table 2).
3. Discussion
Some Micrurus venoms have previously been shown to act as
anticoagulants, but this study demonstrates that in vitro evidence
for this activity can be found throughout the genus and is
particularly potent in M. laticollaris. The fact that these venoms
inhibit clots that are produced by the addition of FXa is strong
evidence that they inhibit a clotting factor downstream of FXa in
the common pathway. While there are positive feedback loops
between the common pathway and the two upstream pathways
Fig. 1. A: Dose-response curves showing the anticoagulant effect of Micrurus
venoms on the clotting time in a prothrombinase inhibition assay (note logarithmic
scale of venom concentration). Symbols are used to differentiate M. laticollaris
(~)—which is by far the most potent anticoagulant venom—from the other four
anticoagulant venoms (■) and those venoms with little to no effect ().
B: Phylogeny of the species studied colored according to the area under the doseresponse curves from subfigure A (exact values are listed by each taxon). Topology
of the phylogeny is adapted from Ref. (Lomonte et al. (2016)).
which we did not directly test, the factors in those other parts of
the coagulation cascade are rarely targeted by anticoagulant
venoms and a venom that only inhibited a factor on one of those
other branches would be unlikely to produce the dramatic results
we see in an assay where the common pathway is directly
stimulated. We only observed weak anticoagulant activity in the
preliminary assays which measured clotting time after incubating
the venom with FXa, fibrinogen, or thrombin and then adding
other factors necessary to form a clot (plasma, thrombin, or
94
D. Dashevsky et al. / Toxicology Letters 337 (2021) 91–97
Fig. 2. Area under the curve of clotting time produced by the five most effective
Micrurus venoms in a FXa addition assay alone, incubated with antivenom, or
incubated with varespladib.
Fig. 3. Concentration curves showing the effect of phospholipid concentration on
our prothrombinase inhibition assay. Error bars represent standard deviation
around the mean for each point.
Table 2
Results of in vivo clotting assay.
mg
Venom (mouse
)
Route of administration
Clot formation
N
15
10
5
PBS
35
30
20
PBS
I.V.
I.V.
I.V.
I.V.
I.P.
I.P.
I.P.
I.P.
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
6
6
6
6
6
6
6
6
fibrinogen respectively). This indicates that those specific factors
are not the target of these venoms.
The ability of varespladib to prevent these anticoagulant effects
is consistent with the hypothesis that the toxins responsible for
this anticoagulant activity belong to the PLA2 family. Despite this,
the strongest anticoagulant venoms were not limited to species
whose venoms have been shown to be dominated by PLA2s, nor did
anticoagulant activity follow an obvious phylogenetic pattern
(Fig. 1B). M. fulvius, M. laticollaris, and M. tener all have PLA2-heavy
venoms and belong to the long-tailed clade of coral snakes while
M.ibiboboca and M. obscurus are known to primarily express 3FTx
in their venoms and belong to the short-tailed clade (Lomonte
et al., 2016; Roze, 1996; Campbell and Lamar, 2004). Since these
species produce relatively few PLA2s, yet still inhibit coagulation,
our results suggest that the anticoagulant PLA2s may be quite
potent, exerting these effects even at relatively low concentrations.
There was a similar mix of compositions within the venoms that
showed little to no anticoagulant effect: the venoms of M. browni
and M. diastema are largely composed of PLA2s and that of M.
distans is likely similar due to its close relation (Lomonte et al.,
2016; Roze, 1996; Campbell and Lamar, 2004); on the other hand,
M. altirostris, M. corallinus,
M. pyrrhocryptus, and M. surinamensis have 3FTx-heavy venoms
(Lomonte et al., 2016; Olamendi-Portugal et al., 2018). The
decoupling of PLA2 expression in the venom and anticoagulant
potency raises questions about whether these toxins inhibit
coagulation factors specifically or if the anticoagulant effect we
observe is merely a side effect of enzymatic cleavage of
phospholipids.
We included phospholipid as a cofactor in the assay and small
amounts were present in the plasma (Krawczyk et al., 1996), it is
possible that these PLA2 toxins produce their anticoagulant effect
by hydrolyzing a large portion of the phospholipids which would
make it next to impossible for the prothrombinase complex to
assemble (Suttie and Jackson, 1977). Previous research on other
Pseudechis venoms shows that this genus exhibits much greater
variability in the phospholipase enzymatic activity (Goldenberg
et al., 2018) than in the anticoag-ulant effect that these same
venoms produced (Zdenek et al., 2020a). Much like our results
these anticoagulant effects were abolished by the addition of
varespladib to the assay and this effect held true for venoms with
almost no phospholipase enzymatic activity. (Zdenek et al., 2020a)
also conducted even more variants of the assay than were used in
this study and found that experimental designs which initiated the
clotting cascade from farther upstream (which should still have
been inhibited by a lack of phospholipid if that was the mechanism
of those anticoagulant effects) showed much weaker effects than
those designed to target the effect of the venom on the
prothrombinase complex. Other investigations of varespladib’s
potential as a snakebite treatment have shown that it can
effectively inhibit non-enzymatic PLA2s such as neurotoxins
(Lewin et al., 2016; Gutiérrez et al., 2020). Additionally, previous
studies on elapid PLA2 anticoagulants have specifically shown that
they can achieve these effects through non-enzymatic mechanisms (Stefansson et al., 1990; Mounier et al., 2001; Kini, 2005).
While these lines of research suggest that elapid PLA2s need not
necessarily interact with phospholipid to produce anticoagulant
effects, the results of our assay performed at various concentrations of phospholipid suggest that the relevant M. laticollaris
toxins do. The exact nature of this interaction remains unclear,
however. There are two hypotheses to test in future work: First that
enzymatic cleavage of the phosopholipids impedes coagulation;
Second that the toxins compete with PLA2 for binding to a specific
clotting factor. In this case, adding additional phospholipid could
increase the competition at those binding sites and leave more of
the clotting factor free to participate in the cascade. Further
research is necessary to clarify the toxins responsible, their
mechanisms, and the differences between species that can explain
the patterns of our findings.
One of the main findings of this research is that Coralmyn
antivenom does little to impede the anticoagulant activities of
these venoms. It should be noted that this antivenom is produced
from the venom M. nigrocinctus which was not available for us to
include in this study, but this antivenom was still able to
significantly decrease the anticoagulation of M. ibiboboca venom
(which is not particularly closely related a pattern seen in other
D. Dashevsky et al. / Toxicology Letters 337 (2021) 91–97
elapids (Zdenek, op den Brouw et al., 2019), Fig. 1B) and has
previously been shown to neutralize the neurotoxic effects of a
wide range of Micrurus venoms (Yang et al., 2017). We find it
unlikely that the age of this particular batch of antivenom rendered
it ineffective since it did produce an effect on M. ibiboboca and
because this antivenom and others have been shown to retain their
effectiveness long past the original expiry date if stored properly
(O’Leary et al., 2009; Wood et al., 2013; Lister et al., 2017). While
the major clinical concern during severe Micrurus bites primarily
stems from their neurotoxins (Greene, 2020; Bucaretchi et al.,
2016; Canãs et al., 2017; Anwar and Bernstein, 2018; Bisneto et al.,
2020), there are certainly reports of patients who display
coagulopathies as additional complications and our results suggest
these could be particularly severe in cases of envenomation by M.
laticollaris (Cecchini et al., 2005; Oliveira et al., 2017; Rey-Suárez
et al., 2017). This research suggests that, in such cases, Coralmyn is
unlikely to alleviate those symptoms and they may have to be
treated using other therapeutics such as varespladib.
Interestingly, our in vivo experiments showed no evidence of an
anticoagulant effect of M. laticollaris venom. This strongly contrasts
with the in vitro tests performed here and therefore requires
further investigation. Unfortunately, reported clinical cases of
Micrurus envenomation are scarce or, in the case of M. laticollaris,
completely nonexistent. There is, nonetheless, available clinical
evidence for M. fulvius envenomations where no coagulopathies
were observed (Wood et al., 2013); a review of Micrurus
envenomations in Brazil also reported no coagulation abnormalities (Bucaretchi et al., 2016). This could suggest that, even if there
are anticoagulant PLA2s in these venoms, they have little relevance
in human envenomation, perhaps due to PLA2 pharmacokinetics or
the PLA2s involved in the anticoagulant effect having other, more
clinically relevant, molecular targets. The experimental conditions
used for the in vivo tests could also be responsible for the
discrepancy with in vitro observations: it is a binary test conducted
in mice that does not allow the description of specific coagulation
parameters. We were unable to test higher concentrations of
venom in this assay due to the neurotoxicity of the venom. It is
possible that any anticoagulant toxins may affect mice differently
than humans or that the relative size may alter the relative impact
of different sorts of toxins; both taxon specificity and the blood
volume of the victim are important for the action of coagulatoxins
from other snake venoms (Sousa et al., 2018; Zdenek, Hay et al.,
2019; Herrera et al., 2012; Zdenek et al., 2020b). Further research
may examine some of these avenues or use more detailed in vivo
methods to clarify the implications of our in vitro findings in
human envenomation. Our results showing that the anticoagulant
effects of the venom diminished when higher quantities of
phospholipid were added to the assay could be another avenue
to help explain the in vitro / in vivo discrepancy. The abundance of
phospholipids in the living mice may have been sufficient to
suppress the anticoagulant effect below the threshold where our
assay would be able to measure it. This study contributes to two
growing bodies of evidence: the aforementioned anticoagulant
properties of Micrurus venoms and the efficacy of varespladib as a
potential treatment for envenomation. While anticoagulant toxins
in Micrurus venoms are less likely to result in fatality than are
neurotoxins, their lack of neutralization by antivenom is cause for
concern. These results reinforce previous findings that varespladib
can be an effective treatment against toxins from a wide range of
species that exhibit an equally wide range of biological activities.
Antivenoms are typically stocked in urban centers due to logistical
(e.g. the need to maintain a cold chain) or clinical (e.g. potential
side effects necessitating additional treatment) requirements.
However, most bites occur in rural areas; this makes varespladib
attractive as a temperature-stable remote first-aid treatment to
95
stabilize patients en route to a hospital which carries antivenom, a
journey that may take hours or days.
4. Materials and methods
Some lyophilized venoms were sourced from long-term
cryogenic collections in the Toxin Evolution Lab while others
were provided by Nathaniel Frank of MToxins Venom Lab,
Alejandro Alagon of Universidad Nacional Autónoma de México,
and Ana Moura da Silva of Instituto Butantan. Collection of these
samples was covered by ICMBio permits 57585 and 66597. These
venoms were resuspended in water, centrifuged (4C, 5 min at
14,000 RCF), and diluted into a solution of 1 mg
mL of venom in a 1:1
mixture of water and glycerol. Protein concentrations were
measured using a NanoDrop 2000 UV–vis Spectrophotometer
(Thermofisher, Sydney, NSW, Australia).
The Australian Red Cross provided healthy human plasma
(Research agreement #18-03QLD 09 and 16-04QLD-10 as well as
University of Queensland Human Ethics Committee Approval
#2016000256). This platelet depleted plasma is provided in 3.2%
citrated condition which removes Ca2+ through chelation to
prevent the spontaneous formation of clots. The plasma from
batches 6181682 and 6185873 was pooled together then divided
into 1 ml aliquots, flash-frozen, and stored at 80 C until use. All
venom and plasma work was undertaken under University of
Queensland Biosafety Approval #IBC134BSBS2015.
We carried out plasma coagulation assays on a Stago STA-R Max
hemostasis analyzer (Stago, Asnires sur Seine, France). Before
beginning the assays we thawed the plasma in a 37 C water bath.
mg
For these assays we diluted the 1 mg
mL venom stocks down to 0.1 mL
using Owren Koller (OK) Buffer (Stago Catalog 00360). Our
coagulation assays include calcium (Stago catalog # 00367) and
phospholipid (Stago catalog #00597) because they are necessary
cofactors for the clotting cascade and are no longer present in the
plasma as provided. The fibrinogen destruction assay has only been
briefly alluded to previously (Debono et al., 2019) and is performed
by incubating the 50 mL of venom with 50 mL of calcium, 50 mL of
phospholipid, and 75 mL of human fibrinogen (4 mg
mL, Lot F3879,
Sigma Aldrich, St. Louis, Missouri, United States) for 1 h at 37 C.
After the incubation, the addition of 25 mL of thrombin (Stago
Catalog #00611) initiates clotting of any remaining fibrinogen and
the result of the assay is the time it takes to form a clot. The plasma
clotting, FXa inhibition,
thrombin inhibition, and prothrombinase inhibition assays used
here have been described in more detail previously (Rogalski et al.,
2017; Zdenek et al., 2020a, Zdenek, Hay et al., 2019; Youngman et al.,
2019). Since the prothrombin inhibition assay is central to this paper,
a brief description of this protocol follows: we incubated 50 mL of the
dilute venom stock with 75 mL of plasma, 50 mL of 0.025 M Ca2+, and
50 mL of phospholipid at 37 C for 120 s before adding 25
mL of FXa (Stago catalog # 00311) to stimulate a clot from the
beginning of the common pathway. To vary the amount of
phospholipid in the assay we simply altered the amount of OK
buffer which was used to resuspend the powdered phospholipid.
In vivo coagulation tests were performed using white mice of
ICR strain with the protocol described in the manual of laboratory
procedures by (Instituto Clodomiro Picado (2007)), with some
modifications. Briefly, different amounts of venom were administered i.v. or i.p. in a final volume of 0.2 mL. After 1 h, 200 mL of blood
was taken in glass capillaries and the mice were immediately
sacrificed. The samples were left at room temperature (22–25 C)
for two hours. Finally, the capillary tubes were broken to observe if
there was clot formation. Bothrops asper venom was used as a
positive control and PBS as negative control.
96
D. Dashevsky et al. / Toxicology Letters 337 (2021) 91–97
We tested the effects of Coralmyn (Instituto Bioclon, Mexico
City, Mexico: Lot: B-2D-06) and LY315920 (varespladib) by
replacing the 0.025 M Ca2+ with a solution made of either 5%
Coralmyn (reconstituted according to the package directions) +
95% 0.025 M Ca2+ and 1% LY315920 (reconstituted according to the
package directions) + 99% 0.025 M Ca2+. Since our assay included
excess Ca2+, this small decrease in concentration did not affect the
negative control clotting times using these solutions (Tukey’s HSD,
p > 0.05).
Transparency document
The Transparency document associated with this article can be
found in the online version.
Declaration of Competing Interest
The authors declare that they have no known competing
financial interests or personal relationships that could have
appeared to influence the work reported in this paper.
Acknowledgements
DD was funded by a UQ Centennial Scholarship from The
University of Queensland, a Research Training Program scholarship
from the Australian Government Department of Education and
Training, and a CSIRO Early Research Career Postdoctoral Fellowship from the Commonwealth Science & Industry Research
Organisation. JAPJ was funded by the Fundação de Amparo á
Pesquisa do Estado de São Paulo under the grant 2018/25749-8.
BGF was funded by Australian Research Council Grant
DP190100304.
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.toxlet.2020.11.010.
References
Alvarado, Jorge, Gutiérrez, José María, 1988. Anticoagulant effect of myotoxic
phospholipase A 2 isolated from the venom of the snake Bothrops asper
(Viperidae). Rev. Biol. Trop. 36 (2B), 563–565.
Anwar, Mehruba, Bernstein, Jeffrey N., 2018. North American Coral snake
envenomation. In: Vogel, Carl-Wilhelm, Seifert, Steven A., Tambourgi, Denise V.
(Eds.), Clinical Toxinology in Australia, Europe, and Americas. Springer
Netherlands, Dordrecht, pp. 169–178.
Baumann, Kate, Dashevsky, Daniel, Sunagar, Kartik, Fry, Bryan, 2018. Scratching the
surface of an itch: molecular evolution of Aculeata venom allergens. J. Mol. Evol.
86 (7 August), 484–500.
Bisneto, Pedro Ferreira, Alcântara, João Arthur, Silva, Iran Mendonçada, de Almeida
Gon, Jacqueline, Sachett, calves, Bernarde, Paulo Sergio, Monteiro, Wuelton
Marcelo, Kaefer, Igor Luis, 2020. Coral snake bites in Brazilian Amazonia:
perpetrating species, epidemiology and clinical aspects. Toxicon 175 (February),
7–18.
Bittenbinder, Mátyás A., Zdenek, Christina N., op den Brouw, Bianca, Youngman,
Nicholas J., Dobson, James S., Naude, Arno, Vonk, Freek J., Fry, Bryan G., 2018.
Coagulotoxic cobras: clinical implications of strong anticoagulant actions of
african spitting Naja venoms that are not neutralised by antivenom but are by
LY315920 (Varespladib). Toxins 10 (12 December), 516.
Bittenbinder, Mátyás A., Zdenek, Christina N., op den Brouw, Bianca, Youngman,
Nicholas J., Dobson, James S., Naude, Arno, Vonk, Freek J., Fry, Bryan G., 2019.
Differential destructive (non-clotting) fibrinogenolytic activity in Afro-Asian
elapid snake venoms and the links to defensive hooding behavior. Toxicology in
Vitro (June) .
Bravo-Vega, Carlos A., Cordovez, Juan M., Renjifo-Ibez, Camila, Santos-Vega,
Mauricio, Sasa, Mahmood, 2019. Estimating snakebite incidence from
mathematical models: a test in Costa rica. PLoS Negl. Trop. Dis. 13 (12
December), e0007914.
Bucaretchi, Fábio, Capitani, Eduardo Mello De, Vieira, Ronan José, Rodrigues, Cinthia
K., Zannin, Marlene, Da Silva Jr., Nelson J., Casais-e-Silva, Luciana L., Hyslop,
Stephen, 2016. Coral snake bites (Micrurus spp.) in Brazil: a review of literature
reports. Clin. Toxicol. 54 (3 March), 222–234.
Campbell, Jonathan A., Lamar, William W., 2004. The Venomous Reptiles of the
Western Hemisphere. Cornell University Press, Ithaca, NY March.
Canãs, Carlos A., Castro-Herrera, Fernando, Valencia, Santiago Castanõ, 2017.
Envenomation by the red-tailed coral snake (Micrurus mipartitus) in Colombia. J.
Venom. Anim. Toxins Incl. Trop. Dis. 23 (1), 9.
Castillo-Beltrán, María Carlina, Hurtado-Gómez, Juan Pablo, Corredor-Espinel,
Vladimir, Javier Ruiz-Gómez, Francisco, 2019. A polyvalent coral snake
antivenom with broad neutralization capacity. PLoS Negl. Trop. Dis. 13 (3
March), e0007250.
Cecchini, Alessandra L., Marcussi, Silvana, Silveira, Lucas B., Borja-Oliveira, Caroline
R., Rodrigues-Simioni, Léa, Amara, Susan, Stábeli, Rodrigo G., Giglio, José R.,
Arantes, Eliane C., Soares, Andreimar M., 2005. Biological and enzymatic
activities of Micrurus sp. (Coral) snake venoms. Comp. Biochem. Physiol., Part A
Mol. Integr. Physiol. 140 (1 January), 125–134.
Debono, Jordan, Bos, Mettine H.A., Coimbra, Francisco, Ge, Lilin, Frank, Nathaniel,
Kwok, Hang Fai, Fry, Bryan G., 2019. Basal but divergent: clinical implications of
differential coagulotoxicity in a clade of Asian vipers. Toxicology in Vitro 58
(August), 195–206.
Earl, S., Sunagar, K., Jackson, T.N.W., Reek, T., Fry, B.G., 2015. Factor Va enzymes.
Venomous Reptiles and Their Toxins: Evolution, Pathophysiology and
Biodiscovery. Oxford University Press, New York, NY, USA, pp. 255–260.
Fry, Bryan, 2018. Snakebite: when the human touch becomes a bad touch. Toxins 10
(4 April), 170.
Goldenberg, Jonathan, Cipriani, Vittoria, Jackson, Timothy N.W., Arbuckle, Kevin,
Debono, Jordan, Dashevsky, Daniel, Panagides, Nadya, Ikonomopoulou, Maria P.,
Koludarov, Ivan, Li, Bin, Santana, Renan Castro, Nouwens, Amanda, Jones, Alun,
Hay, Chris, Dunstan, Nathan, Allen, Luke, Bush, Brian, Miles, John J., Ge, Lilin,
Kwok, Hang Fai, Fry, Bryan G., 2018. Proteomic and functional variation within
black snake venoms (Elapidae: Pseudechis). Comp. Biochem. Physiol. Part C
Toxicol. Pharmacol. 205 (February), 53–61.
Greene, Spencer, 2020. Coral snake envenomations in central and South America.
Curr. Trop. Med. Rep.(January) .
Gutiérrez, José María, Lewin, Matthew R., Williams, David J., Lomonte, Bruno, 2020.
Varespladib (LY315920) and methyl varespladib (LY333013) abrogate or delay
lethality induced by presynaptically acting neurotoxic snake venoms. Toxins 12
(2 February), 131.
Habib, Abdulrazaq G., Kuznik, Andreas, Hamza, Muhammad, Abdullahi, Maryam I.,
Chedi, Basheer A., Chippaux, Jean-Philippe, Warrell, David A., 2015. Snakebite is
under appreciated: appraisal of burden from West Africa. PLoS Negl. Trop. Dis. 9
(9 September), e0004088.
Harrison, Robert A., Hargreaves, Adam, Wagstaff, Simon C., Faragher, Brian, Lalloo,
David G., 2009. Snake envenoming: a disease of poverty. PLoS Negl. Trop. Dis. 3
(12 December), e569.
Herrera, María, Fernández, Julián, Vargas, Mariángela, Villalta, Mauren, Segura,
Álvaro, León, Guillermo, Angulo, Yamileth, Paiva, Owen, Matainaho, Teatulohi,
Jensen, Simon D., Winkel, Kenneth D., Calvete, Juan J., Williams, David J.,
Gutiérrez, José María, 2012. Comparative proteomic analysis of the venom of the
taipan snake, Oxyuranus scutellatus, from Papua New Guinea and Australia: role
of neurotoxic and procoagulant effects in venom toxicity. J. Proteomics 75 (7),
2128–2140 Publisher: Elsevier.
Instituto Clodomiro Picado, 2007. Determinación de Actividades Tóxicas de
Venenos de Serpientes y su Neutralización por Antivenenos. Manual de
Métodos de Laboratorio. Facultad de Microbiología. Universidad de Costa Rica,
San Jos, Costa Rica.
Jean Philippe Chippaux, 1998. Snake-bites: appraisal of the global situation. Bulletin
of the World Health organization 76 (5), 515.
Kasturiratne, Anuradhani, Rajitha Wickremasinghe, A., de Silva, Nilanthi, Kithsiri
Gunawardena, N., Pathmeswaran, Arunasalam, Premaratna, Ranjan, Savioli,
Lorenzo, Lalloo, David G., Janaka de Silva, H., 2008. The global burden of
snakebite: a literature analysis and modelling based on regional estimates of
envenoming and deaths. PLoS Med. 5 (11 November), e218.
Kerns, Robnet T., Kini, R. Manjunatha, Stefansson, Steingrimur, Evans, Herbert J.,
1999. Targeting of venom phospholipases: the strongly anticoagulant
phospholipase A2 from Naja nigricollis venom binds to coagulation factor Xa to
inhibit the prothrombinase complex. Arch. Biochem. Biophys. 369 (1
September), 107–113.
Kini, R. Manjunatha, 2003. Excitement ahead: structure, function and mechanism of
snake venom phospholipase A2 enzymes. Toxicon 42 (8 December), 827–840.
Kini, R. Manjunatha, 2005. Structure-function relationships and mechanism of
anticoagulant phospholipase A2 enzymes from snake venoms. Toxicon 45 (8
June), 1147–1161.
ska, Anna, Marczewski,
_
Krawczyk, Wojciech, Ledwozyw,
Andrzej, Dmoszyn
Krzysztof, 1996. Human erythropoietin improves blood plasma phospholipids
concentration in chronically hemodialyzed patients. Nephron 72 (1), 109–110
Publisher: Karger Publishers.
Lewin, Matthew, Samuel, Stephen, Merkel, Janie, Bickler, Philip, 2016. Varespladib
(LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom
phospholipase A2 and a possible pre-referral treatment for envenomation.
Toxins 8 (9 September), 248.
Lewin, Matthew R., Gilliam, Lyndi L., Gilliam, John, Samuel, Stephen P., Bulfone,
Tommaso C., Bickler, Philip E., Gutiérrez, José María, 2018. Delayed LY333013
(Oral) and LY315920 (Intravenous) reverse severe neurotoxicity and rescue
juvenile pigs from lethal doses of Micrurus fulvius (Eastern coral snake) venom.
Toxins 10 (11 November), 479.
Lister, Callum, Arbuckle, Kevin, Jackson, Timothy N.W., Debono, Jordan, Zdenek,
Christina N., Dashevsky, Daniel, Dunstan, Nathan, Allen, Luke, Hay, Chris, Bush,
D. Dashevsky et al. / Toxicology Letters 337 (2021) 91–97
Brian, Gillett, Amber, Fry, Bryan G., 2017. Catch a tiger snake by its tail:
differential toxicity, co-factor dependence and antivenom efficacy in a
procoagulant clade of Australian venomous snakes. Comp. Biochem. Physiol.
Part C Toxicol. Pharmacol. 202 (November), 39–54.
Lomonte, Bruno, Rey-Suárez, Paola, Fernández, Julián, Sasa, Mahmood, Pla, Davinia,
Vargas, Nancy, Bénard-Valle, Melisa, Sanz, Libia, Corrêa-Netto, Carlos, Núñez,
Vitelbina, Alape-Girón, Alberto, Alagón, Alejandro, Gutiérrez, José María,
Calvete, Juan J., 2016. Venoms of Micrurus coral snakes: evolutionary trends in
compositional patterns emerging from proteomic analyses. Toxicon 122
(September), 7–25.
Longbottom, Joshua, Shearer, Freya M., Devine, Maria, Alcoba, Gabriel, Chappuis,
Francois, Weiss, Daniel J., Ray, Sarah E., Ray, Nicolas, Warrell, David A., Ruiz de
Castaeda, Rafael, Williams, David J., Hay, Simon I., Pigott, David M., 2018.
Vulnerability to snakebite envenoming: a global mapping of hotspots. Lancet
392 (10148 August), 673–684.
Manock, Stephen R., Suarez, German, Graham, David, Avila-Aguero, María L.,
Warrell, David A., 2008. Neurotoxic envenoming by South American coral snake
(Micrurus lemniscatus helleri): case report from eastern Ecuador and review.
Trans. R. Soc. Trop. Med. Hyg. 102 (11 November), 1127–1132.
Margres, Mark J., Aronow, Karalyn, Loyacano, Jacob, Rokyta, Darin R., 2013. The
venom-gland transcriptome of the eastern coral snake (Micrurus fulvius) reveals
high venom complexity in the intragenomic evolution of venoms. BMC
Genomics 14 (1), 1.
Mohapatra, Bijayeeni, Warrell, David A., Suraweera, Wilson, Bhatia, Prakash,
Dhingra, Neeraj, Jotkar, Raju M., Rodriguez, Peter S., Mishra, Kaushik, Whitaker,
Romulus, Jha, Prabhat, for the Million Death Study Collaborators, 2011.
Snakebite Mortality in India: A Nationally Representative Mortality Survey.
PLoS Negl. Trop. Dis. 5 (4 April), e1018.
Mounier, Carine M., Bon, Cassian, Kini, R. Manjunatha, 2001. Anticoagulant venom
and mammalian secreted phospholipases A2: proteinversus phospholipiddependent mechanism of action. Pathophysiol. Haemost. Thromb. 31 (3–6),
279–287.
Mukherjee, Ashis K., 2014. The pro-coagulant fibrinogenolytic serine protease
isoenzymes purified from Daboia russelii russelii venom coagulate the blood
through factor V activation: role of glycosylation on enzymatic activity. PLoS
One 9 (2 February), e86823.
O’Leary, Margaret A., Kornhauser, Rachelle S., Hodgson, Wayne C., Isbister, Geoffrey
K., 2009. An examination of the activity of expired and mistreated commercial
Australian antivenoms. Trans. R. Soc. Trop. Med. Hyg. 103 (9), 937–942.
Olamendi-Portugal, Timoteo, Batista, César V.F., Pedraza-Escalona, Martha,
RestanoCassulini, Rita, Zamudio, Fernando Z., Benard-Valle, Melisa, Rafael de
Roodt, Adolfo, Possani, Lourival D., 2018. New insights into the proteomic
characterization of the coral snake Micrurus pyrrhocryptus venom. Toxicon 153
(October), 23–31.
Oliveira, Fabianada Rocha, Noronha, Mariadas Dores Nogueira, Lozano, Jorge Luis
Lopez, 2017. Biological and molecular properties of yellow venom of the
Amazonian coral snake Micrurus surinamensis. Rev. Soc. Bras. Med. Trop. 50 (3
June), 365–373.
Rey-Suárez, Paola, Núñez, Vitelbina, Saldarriaga-Córdoba, Mónica, Lomonte, Bruno,
2017. Primary structures and partial toxicological characterization of two
phospholipases A 2 from Micrurus mipartitus and Micrurus dumerilii coral snake
venoms. Biochimie 137 (June), 88–98.
Rogalski, Aymeric, Soerensen, Christoffer, op den Brouw, Bianca, Lister, Callum,
Dashevsky, Daniel, Arbuckle, Kevin, Gloria, Alexandra, Zdenek, Christina N.,
Casewell, Nicholas R., Gutirrez, José María, Wolfgang, Wüster, Ali, Syed A.,
Masci, Paul, Rowley, Paul, Frank, Nathaniel, Fry, Bryan G., 2017. Differential
procoagulant effects of saw-scaled viper (Serpentes: Viperidae: Echis) snake
venoms on human plasma and the narrow taxonomic ranges of antivenom
efficacies. Toxicol. Lett. 280 (October), 159–170.
Roze, Janis A., 1996. Coral Snakes of the Americas: Biology, Identification, and
Venoms. Krieger Publishing Company.
Sanz, Libia, Quesada-Bernat, Sarai, Ramos, Tyelli, Casais-e-Silva, Luciana L.,
CorrêaNetto, Carlos, Silva-Haad, Juan José, Sasa, Mahmood, Lomonte, Bruno,
Calvete, Juan J., 2019. New insights into the phylogeographic distribution of the
3FTx/PLA2 venom dichotomy across genus Micrurus in South America. J.
Proteomics 200 (May), 90–101.
Sharma, Sanjib K., Chappuis, FranScois, Jha, Nilhambar, Bovier, Patrick A., Loutan,
Louis, Koirala, Shekhar, 2004. Impact of snake bites and determinants of fatal
outcomes in Southeastern Nepal. Am. J. Trop. Med. Hyg. 71 (2 August), 234–238
Publisher: The American Society of Tropical Medicine and Hygiene.
Silva, Ageane Motada, Fonseca, Wirven Limada, de Araujo Valente Neto, Edgar,
Bisneto, Pedro Ferreira, Contreras-Bernal, Jorge, Sachett, Jacqueline, Monteiro,
Wuelton Marcelo, Bernarde, Paulo Sergio, 2019. Envenomation by Micrurus
annellatus bolivianus (Peters, 1871) coral snake in the western Brazilian Amazon.
Toxicon 166 (August), 34–38.
Smith, Stephanie A., Travers, Richard J., Morrissey, James H., 2015. How it all starts:
initiation of the clotting cascade. Crit. Rev. Biochem. Mol. Biol. 50 (4 July), 326–
336. doi:http://dx.doi.org/10.3109/10409238.2015.1050550 Publisher: Taylor &
Francis eprint.
Sousa, Leijiane F., Zdenek, Christina N., Dobson, James S., op den Brouw, Bianca,
Coimbra, Francisco, Gillett, Amber, Del-Rei, Tiago, Chalkidis, Hipócrates,
Sant’Anna, Sávio, Teixeira-da-Rocha, Marisa, Grego, Kathleen, Travaglia
Cardoso, Silvia, Moura da Silva, Ana, Fry, Bryan G., 2018. Coagulotoxicity of
Bothrops (Lancehead Pit-Vipers) venoms from Brazil: differential biochemistry
and antivenom efficacy resulting from prey-driven venom variation. Toxins 10
(10), 411.
97
Stefansson, Steingrimur, Kini, R. Manjunatha, Evans, Herbert J., 1990. The basic
phospholipase A2 from Naja nigricollis venom inhibits the prothrombinase
complex by a novel nonenzymatic mechanism. Biochemistry 29 (33 August),
7742–7746.
Strauch, Marcelo Abrahão, Souza, Guilherme Jones, Pereira, Jordana Nahar, Ramos,
Tyellidos Santos, Cesar, Marcelo Oliveira, Tomaz, Marcelo Amorim, MonteiroMachado, Marcos, Neto, Fernando Chagas Patrão, Melo, Paulo A., 2018. True or
false coral snake: is it worth the risk? A Micrurus corallinus case report. J. Venom.
Anim. Toxins Incl. Trop. Dis. 24 (1 December) .
Sunagar, K., Jackson, T.N.W., Reeks, T., Fry, B.G., 2015a. Group I phospholipase A2
enzymes. Venomous Reptiles and Their Toxins: Evolution, Pathophysiology and
Biodiscovery. Oxford University Press, New York, NY, USA.
Sunagar, K., Tsai, H., Lomonte, B., Jackson, T.N.W., Fry, B.G., 2015b. Group II phospholi
pase A2 enzymes. Venomous Reptiles and Their Toxins: Evolution,
Pathophysiology, and Biodiscovery. Oxford University Press, New York, NY, USA,
pp. 327–334.
Suttie, J.W., Jackson, C.M., 1977. Prothrombin structure, activation, and biosynthesis.
Physiological Reviews. January. Publisher: American Physiological Society,
Bethesda, MD.
Trabi, M., Sunagar, K., Jackson, T.N.W., Fry, B.G., 2015. Factor Xa proteins. Venomous
Reptiles and Their Toxins: Evolution, Pathophysiology and Biodiscovery. Oxford
University Press, New York, NY, USA, pp. 261–266.
Utkin, Yuri, Sunagar, Kartik, Jackson, Timothy N.W., Reeks, T., Fry, Bryan G., 2015.
Three-finger toxins (3FTxs). In: Fry, B.G. (Ed.), Venomous Reptiles and Their
Toxins: Evolution, Pathophysiology and Biodiscovery. Oxford University Press,
pp. 215–227.
Vergara, Irene, Pedraza-Escalona, Martha, Paniagua, Dayanira, Restano-Cassulini,
Rita, Zamudio, Fernando, Batista, Cesar V.F., Possani, Lourival D., Alagón,
Alejandro, 2014. Eastern coral snake Micrurus fulvius venom toxicity in mice is
mainly determined by neurotoxic phospholipases A2. J. Proteomics 105 (June),
295–306.
Verheij, Hubertus M., Boffa, Marie-Claire, Rothen, Christophe, Bryckaert, MarieClaude, Verger, Robert, Haas, Gerard H., 1980. Correlation of enzymatic activity
and anticoagulant properties of phospholipase A2. Eur. J. Biochem. 112 (1
November), 25–32.
Victor Hoffbrand, A., Steensma, David P., 2019. Hoffbrand’s Essential Haematology.
John Wiley & Sons.
Weisel, John W., 2005. Fibrinogen and Fibrin. Advances in Protein Chemistry,
Volume 70 of Fibrous Proteins: Coiled-coils, Collagen and Elastomers. Academic
Press, pp. 247–299 January.
WHO Neglected Tropical Diseases (Ed.), 2019. Snakebite Envenoming: a Strategy for
Prevention and Control. World Health Organization, Geneva.
Wood, A., Schauben, J., Thundiyil, J., Kunisaki, T., Sollee, D., Lewis-Younger, C.,
Bernstein, J., Weisman, R., 2013. Review of Eastern coral snake (Micrurus fulvius
fulvius) exposures managed by the Florida poison Information Center Network:
1998-2010. Clin. Toxicol. 51 (8 September), 783–788.
Xie, Chunfang, Albulescu, Laura-Oana, Still, Kristina B.M., Slagboom, Julien, Zhao,
Yumei, Jiang, Zhengjin, Somsen, Govert W., Vonk, Freek J., Casewell, Nicholas R.,
Kool, Jeroen, 2020. Varespladib inhibits the phospholipase A2 and
coagulopathic activities of venom components from hemotoxic snakes.
Biomedicines 8 (6 June), 165.
Yang, Daryl C., Dobson, James, Cochran, Chip, Dashevsky, Daniel, Arbuckle, Kevin,
Bénard-Valle, Melisa, Boyer, Leslie, Alagón, Alejandro, Hendrikx, Iwan, Hodgson,
Wayne C., Fry, Bryan G., 2017. The Bold and the Beautiful: a Neurotoxicity
Comparison of New World Coral Snakes in the Micruroides and Micrurus
Genera and Relative Neutralization by Antivenom. Neurotox. Res. 32 (3
October), 487–495.
Youngman, Nicholas J., Zdenek, Christina N., Dobson, James S., Bittenbinder,
Mátyás A., Gillett, Amber, Hamilton, Brett, Dunstan, Nathan, Allen, Luke,
Veary, Andrew, Veary, Elle, Fry, Bryan G., 2019. Mud in the blood: novel potent
anticoagulant coagulotoxicity in the venoms of the Australian elapid snake
genus Denisonia (mud adders) and relative antivenom efficacy. Toxicol. Lett.
302 (March), 1–6.
Youngman, Nicholas J., Walker, Andrew, Naude, Arno, Coster, Kristian, Sundman,
Eric, Fry, Bryan G., 2020. Varespladib (LY315920) neutralises phospholipase A2
mediated prothrombinase inhibition induced by Bitis snake venoms. Comp.
Biochem. Physiol. Part C Toxicol. Pharmacol. 236 (October), 108818.
Zdenek, Christina N., op den Brouw, Bianca, Dashevsky, Daniel, Gloria, Alexandra,
Youngman, Nicholas J., Watson, Ebony, Green, Patrick, Hay, Chris, Dunstan,
Nathan, Allen, Luke, Fry, Bryan G., 2019. Clinical implications of convergent
procoagulant toxicity and differential antivenom efficacy in Australian elapid
snake venoms. Toxicol. Lett. 316 (November), 171–182.
Zdenek, Christina N., Youngman, Nicholas J., Hay, Chris, Dobson, James, Dunstan,
Nathan, Allen, Luke, Milanovic, Leontina, Fry, Bryan G., 2020a. Anticoagulant
toxicity of black snake (Elapidae: pseudechis) venoms: potency, mechanisms,
and antivenom efficacy. Toxicol. Lett.(May) .
Zdenek, Christina N., Hay, Chris, Arbuckle, Kevin, Jackson, Timothy N.W., Bos,
Mettine H.A., op den Brouw, Bianca, Debono, Jordan, Allen, Luke, Dunstan,
Nathan, Morley, Terry, Herrera, Mara, Gutiérrez, José M., Williams, David J., Fry,
Bryan G., 2019. Coagulotoxic effects by brown snake (Pseudonaja) and taipan
(Oxyuranus) venoms, and the efficacy of a new antivenom. Toxicol. Vitr. 58
(August), 97–109.
Zdenek, Christina N., Llinas, Joshua, Dobson, James, Allen, Luke, Dunstan, Nathan,
Sousa, Leijiane F., Ana, M., Silva, Mourada, Fry, Bryan G., 2020b. Pets in peril: the
relative susceptibility of cats and dogs to procoagulant snake venoms. Comp.
Biochem. Physiol. Part C Toxicol. Pharmacol. 236 (October) 108769.